We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”

Learn more about it by watching THIS NOW.

Samir Kaul Biography and Net Worth

Director of Guardant Health

Samir Kaul has served as a member of Guardant Health’s board of directors since April 2014. Mr. Kaul has been a General Partner at Khosla Ventures, a venture capital firm focusing on technology investing, since February 2006 and currently serves on the boards of directors of several private companies. He also served as a member of the board of directors of Gevo, Inc. from March 2013 to May 2014 and Amyris, Inc. from May 2006 to May 2012. Previously, Mr. Kaul was a member of Flagship Pioneering Inc., a venture capital firm, from June 2002 to May 2006. Prior to that, Mr. Kaul worked at the Institute for Genomic Research. Mr. Kaul holds a B.S. degree in biology from the University of Michigan, an M.S. degree in biochemistry from the University of Maryland and an M.B.A. degree from Harvard Business School.

What is Samir Kaul's net worth?: The estimated net worth of Samir Kaul is at least $122,622.39 as of May 5th, 2021. Mr. Kaul owns 4,059 shares of Guardant Health stock worth more than $122,622 as of November 14th. This net worth evaluation does not reflect any other assets that Mr. Kaul may own. Learn More about Samir Kaul's net worth.
How do I contact Samir Kaul?: The corporate mailing address for Mr. Kaul and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Samir Kaul's contact information.
Has Samir Kaul been buying or selling shares of Guardant Health?: Samir Kaul has not been actively trading shares of Guardant Health in the last ninety days. Most recently, Samir Kaul sold 5,000 shares of the business's stock in a transaction on Wednesday, May 5th. The shares were sold at an average price of $142.85, for a transaction totalling $714,250.00. Following the completion of the sale, the director now directly owns 4,059 shares of the company's stock, valued at $579,828.15. Learn More on Samir Kaul's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), and Amirali Talasaz (COO). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, Guardant Health insiders bought shares 1 times. They purchased a total of 2,187 shares worth more than $38,972.34. During the last year, insiders at the sold shares 5 times. They sold a total of 8,996 shares worth more than $246,862.40. The most recent insider tranaction occured on November, 13th when Director Meghan V Joyce sold 2,896 shares worth more than $86,590.40. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 11/13/2024.

Samir Kaul Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/5/2021	Sell	5,000	$142.85	$714,250.00	4,059
4/5/2021	Sell	5,000	$158.56	$792,800.00	4,059
10/16/2020	Sell	10,000	$101.88	$1,018,800.00	4,059
9/17/2020	Sell	10,000	$100.83	$1,008,300.00	4,059
3/4/2020	Sell	25,000	$82.38	$2,059,500.00	1,302

Samir Kaul Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $30.21

$30.03

$31.32

50 Day Range

MA: $23.57

$20.20

$31.61

2 Week Range

Now: $30.21

$15.81

$37.04

Volume

2,020,772 shs

Average Volume

2,071,955 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

The #1 Crypto for AI

From Weiss Ratings | Ad